ALK-Abello A/S Release: FDA Postpones Advisory Committee Meeting for Grass AIT Tablet Due to US Government Shutdown  
10/8/2013 9:56:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALK (ALK-B.CO / OMX:ALK B / AKABY / AKBLF) today announced that due to the US government shutdown, the US Food and Drug Administration (FDA) has temporarily postponed the Allergenic Products Advisory Committee meeting scheduled for 6 November 2013 to discuss the Biologic License Application (BLA) for the investigational grass allergy immunotherapy (AIT) tablet. The FDA has not yet confirmed a new date for the Advisory Committee meeting. ALK will provide an update when additional information becomes available. - See more at:

Help employers find you! Check out all the jobs and post your resume.